These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22300720)

  • 1. Is the pneumococcal vaccine Advance Market Commitment motivating innovation and increasing manufacturing capacity? Some preliminary answers.
    Plahte J
    Vaccine; 2012 Mar; 30(14):2462-6. PubMed ID: 22300720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic perspectives on the advance market commitment for pneumococcal vaccines.
    Snyder CM; Begor W; Berndt ER
    Health Aff (Millwood); 2011 Aug; 30(8):1508-17. PubMed ID: 21821567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advance market commitment for pneumococcal vaccines: putting theory into practice.
    Cernuschi T; Furrer E; Schwalbe N; Jones A; Berndt ER; McAdams S
    Bull World Health Organ; 2011 Dec; 89(12):913-8. PubMed ID: 22271949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public vaccine manufacturing capacity in the Latin American and Caribbean region: current status and perspectives.
    Cortes Mde L; Cardoso D; Fitzgerald J; DiFabio JL
    Biologicals; 2012 Jan; 40(1):3-14. PubMed ID: 22033155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The introduction of new vaccines into developing countries. IV: Global Access Strategies.
    Mahoney RT; Krattiger A; Clemens JD; Curtiss R
    Vaccine; 2007 May; 25(20):4003-11. PubMed ID: 17363119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are advance market commitments for drugs a real advance?
    Scudellari M
    Nat Med; 2011 Feb; 17(2):139. PubMed ID: 21297588
    [No Abstract]   [Full Text] [Related]  

  • 7. Access to vaccine technologies in developing countries: Brazil and India.
    Milstien JB; Gaulé P; Kaddar M
    Vaccine; 2007 Nov; 25(44):7610-9. PubMed ID: 17913312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.
    Perdue ML; Bright RA
    Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers.
    Chandrasekharan S; Amin T; Kim J; Furrer E; Matterson AC; Schwalbe N; Nguyen A
    Vaccine; 2015 Nov; 33(46):6366-70. PubMed ID: 26368398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PneumoADIP: an example of translational research to accelerate pneumococcal vaccination in developing countries.
    Levine OS; Cherian T; Shah R; Batson A
    J Health Popul Nutr; 2004 Sep; 22(3):268-74. PubMed ID: 15609779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing countries roll out pneumococcal vaccine thanks to novel funding scheme.
    Kmietowicz Z
    BMJ; 2010 Dec; 341():c7230. PubMed ID: 21159770
    [No Abstract]   [Full Text] [Related]  

  • 12. The problems and promise of vaccine markets in developing countries.
    Batson A
    Health Aff (Millwood); 2005; 24(3):690-3. PubMed ID: 15886160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New vaccines against otitis media: projected benefits and cost-effectiveness.
    O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
    Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of emerging manufacturers in access to innovative vaccines of public health importance.
    Milstien JB; Kaddar M
    Vaccine; 2010 Feb; 28(9):2115-21. PubMed ID: 20044054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.
    Jadhav S; Datla M; Kreeftenberg H; Hendriks J
    Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine.
    Ray GT
    Expert Rev Vaccines; 2002 Jun; 1(1):65-74. PubMed ID: 12908513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ensuring access to affordable, timely vaccines in emergencies.
    Elder K; Saitta B; Ducomble T; Alia M; Close R; Scheele S; Erickson E; Scourse R; Kahn P; Elder G
    Bull World Health Organ; 2019 Dec; 97(12):851-853. PubMed ID: 31819295
    [No Abstract]   [Full Text] [Related]  

  • 18. Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States.
    Shen AK; Rodewald LE; Birkhead GS
    Pediatrics; 2009 Dec; 124 Suppl 5():S540-7. PubMed ID: 19948586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
    Mangtani P; Roberts JA; Hall AJ; Cutts FT
    Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era.
    Dinleyici EC; Yargic ZA
    Expert Rev Vaccines; 2008 Nov; 7(9):1367-94. PubMed ID: 18980540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.